California court clears Gilead of duty

The California Supreme Court ruled on August 3 that Gilead Sciences did not owe patients a legal duty to develop and commercialize a newer HIV medicine faster than it did. The 6-1 decision ended a closely watched California case brought by roughly 24,000 people who used Gilead’s older tenofovir-based drugs. Justice Joshua Groban, writing for the majority, said the court would not recognize liability for injuries tied to a “concededly nondefective drug” on the theory that a different drug should have been made available sooner. The case is known as *Gilead Tenofovir Cases*. ### What were the patients claiming against Gilead? The plaintiffs were HIV patients who took medicines containing tenofovir disoproxil fumarate, or TDF, a Gilead drug ingredient approved in the United States in 2001. They alleged the medicines contributed to kidney and bone injuries. They did not claim TDF was defectively designed, defectively manufactured, or sold with inadequate warnings, according to accounts of the ruling and the litigation. (yahoo.com) Gilead’s later compound, tenofovir alafenamide, or TAF, became the center of the dispute. Patients argued that TAF was similarly effective with fewer side effects and that Gilead delayed bringing it to market in order to preserve revenue from TDF-based products before patent protections expired. Reuters reported the patients said the delay lasted nearly a decade. (medicaldaily.com) ### Why did the court reject that theory? Justice Joshua Groban wrote that the court was declining to create “sweeping liability” for injuries caused by a nondefective drug because a manufacturer allegedly failed to make a different drug available sooner. He added that imposing that kind of liability would create “substantial burdens” and risk “adverse consequences for pharmaceutical innovation, public health, and patient safety,” according to Reuters’ account of the opinion. (medicaldaily.com) The majority also said the case asked courts and juries to second-guess scientific and commercial decisions about drug development. Medical Daily’s summary of the opinion said the court concluded that such a duty would force hindsight review of complex judgments, including whether available evidence was enough to establish that an alternative product was in fact safer. (yahoo.com) ### What does “no duty to innovate” mean here? The phrase “duty to innovate” describes the negligence theory the plaintiffs were trying to establish. In this case, it meant asking the court to hold that a drugmaker selling an approved, nondefective medicine had a legal obligation to move faster on a newer version that might offer a better safety profile. The California Supreme Court rejected that theory under California tort law. (medicaldaily.com) The ruling was narrow in another respect. Medical Daily reported that the decision did not find either TDF or TAF unsafe and did not change prescribing guidance. It answered a legal question about whether a company can be sued for the pace at which it developed and commercialized a different product. ### How important was this case to the drug industry? (medicaldaily.com) Reuters reported the case was closely followed in the pharmaceutical industry because it tested whether companies could face negligence liability for not spending sooner on alternative products that might reduce side effects. Gilead said after the decision that the ruling was “a victory for all those working to develop improved medical treatments and new medicines.” The company also said the decision supports “American innovation.” (medicaldaily.com) The litigation also carried financial weight for Gilead. Reuters reported that HIV drugs accounted for 70% of Gilead’s $29.4 billion in 2025 revenue. Gilead is based in Foster City, California. ### What happens next in the case? The August 3 opinion reversed a February 2024 California Court of Appeal ruling that had allowed the negligence theory to proceed. (yahoo.com) Reuters said the state high court ordered dismissal of the negligence claims, while Medical Daily described the decision as ending years of litigation over the theory. The next procedural steps will play out in lower court under the California Supreme Court’s ruling in *Gilead Tenofovir Cases*, docket S283862.